{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+of+treatments&page=4", "query": { "intervention": "Combination of treatments", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 12153, "total_pages": 1216, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+of+treatments&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+of+treatments&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T09:48:13.559Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00492687", "title": "Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "San Diego Pacific Oncology & Hematology Associates", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2006-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-10-09T09:48:13.559Z", "location_count": 1, "location_summary": "Encinitas, California", "locations": [ { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00492687" }, { "nct_id": "NCT00667121", "title": "Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Depression", "Hot Flashes", "Psychosocial Effects of Cancer and Its Treatment" ], "interventions": [ { "name": "citalopram hydrobromide", "type": "DRUG" }, { "name": "escitalopram oxalate", "type": "DRUG" }, { "name": "gabapentin", "type": "DRUG" }, { "name": "sertraline hydrochloride", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "venlafaxine", "type": "DRUG" }, { "name": "molecular genetic technique", "type": "GENETIC" }, { "name": "high performance liquid chromatography", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "adjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 88, "start_date": "2011-03-16", "completion_date": "2014-05-27", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-10-09T09:48:13.559Z", "location_count": 6, "location_summary": "Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00667121" }, { "nct_id": "NCT03123016", "title": "Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vitiligo" ], "interventions": [ { "name": "Apremilast", "type": "DRUG" }, { "name": "NB-UVB phototherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2017-04-14", "completion_date": "2019-08-05", "has_results": false, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-09T09:48:13.559Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03123016" }, { "nct_id": "NCT03278106", "title": "TAS-102 in Treating Advanced Biliary Tract Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cholangiocarcinoma", "Stage III Gallbladder Cancer AJCC v7", "Stage IIIA Gallbladder Cancer AJCC v7", "Stage IIIB Gallbladder Cancer AJCC v7", "Stage IV Gallbladder Cancer AJCC v7", "Stage IVA Gallbladder Cancer AJCC v7", "Stage IVB Gallbladder Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2017-10-20", "completion_date": "2021-09-16", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-10-09T09:48:13.559Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03278106" }, { "nct_id": "NCT05183204", "title": "Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Paxalisib", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Ketogenic Diet", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-02-14", "completion_date": "2026-08-10", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-09T09:48:13.559Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05183204" }, { "nct_id": "NCT00667147", "title": "Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Weekly Abraxane and Daily Vandetanib", "type": "DRUG" }, { "name": "Abraxane every three weeks and daily vandetanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2008-03", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-11-19", "last_synced_at": "2026-10-09T09:48:13.559Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00667147" }, { "nct_id": "NCT01490749", "title": "Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Neoplasms, Esophageal" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "XELOX", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2012-02", "completion_date": "2019-02", "has_results": false, "last_update_posted_date": "2019-03-15", "last_synced_at": "2026-10-09T09:48:13.559Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Nashville, Tennessee", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490749" }, { "nct_id": "NCT05883449", "title": "Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Hodgkin Lymphoma", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "AFM13", "type": "DRUG" }, { "name": "AB-101", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affimed GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-10-10", "completion_date": "2025-06-13", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-10-09T09:48:13.559Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Duarte, California • Orange, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05883449" }, { "nct_id": "NCT02995655", "title": "CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndromes", "Acute Myeloid Leukemia", "AML", "MDS" ], "interventions": [ { "name": "CX-01", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Bone marrow biopsy", "type": "PROCEDURE" }, { "name": "Peripheral blood draw", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2017-04-07", "completion_date": "2019-04-29", "has_results": false, "last_update_posted_date": "2019-12-05", "last_synced_at": "2026-10-09T09:48:13.559Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02995655" }, { "nct_id": "NCT02967692", "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Spartalizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 568, "start_date": "2017-02-17", "completion_date": "2024-08-21", "has_results": true, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-10-09T09:48:13.559Z", "location_count": 12, "location_summary": "Encinitas, California • Orange, California • San Francisco, California + 9 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02967692" } ] }